Role of Genetics in Diagnosis and Management of Hypertrophic Cardiomyopathy: A Glimpse into the Future

10Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

Abstract

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy. It follows an autosomal dominant inheritance pattern in most cases, with incomplete penetrance and heterogeneity. It is familial in 60% of cases and most of these are caused by pathogenic variants in the core sarcomeric genes (MYH7, MYBPC3, TNNT2, TNNI3, MYL2, MYL3, TPM1, ACTC1). Genetic testing using targeted disease-specific panels that utilize next-generation sequencing (NGS) and include sarcomeric genes with the strongest evidence of association and syndrome-associated genes is highly recommended for every HCM patient to confirm the diagnosis, identify the molecular etiology, and guide screening and management. The yield of genetic testing for a disease-causing variant is 30% in sporadic cases and up to 60% in familial cases and in younger patients with typical asymmetrical septal hypertrophy. Genetic testing remains challenging in the interpretation of results and classification of variants. Therefore, in 2015 the American College of Medical Genetics and Genomics (ACMG) established guidelines to classify and interpret the variants with an emphasis on the necessity of periodic reassessment of variant classification as genetic knowledge rapidly expands. The current guidelines recommend focused cascade genetic testing regardless of age in phenotype-negative first-degree relatives if a variant with decisive evidence of pathogenicity has been identified in the proband. Genetic test results in family members guide longitudinal clinical surveillance. At present, there is emerging evidence for genetic test application in risk stratification and management but its implementation into clinical practice needs further study. Promising fields such as gene therapy and implementation of artificial intelligence in the diagnosis of HCM are emerging and paving the way for more effective screening and management, but many challenges and obstacles need to be overcome before establishing the practical implications of these new methods.

References Powered by Scopus

Cited by Powered by Scopus

2Citations
5Readers

This article is free to access.

1Citations
11Readers
Get full text
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Abbas, M. T., Baba Ali, N., Farina, J. M., Mahmoud, A. K., Pereyra, M., Scalia, I. G., … Arsanjani, R. (2024, March 1). Role of Genetics in Diagnosis and Management of Hypertrophic Cardiomyopathy: A Glimpse into the Future. Biomedicines. Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/biomedicines12030682

Readers over time

‘24‘2507142128

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 5

83%

Lecturer / Post doc 1

17%

Readers' Discipline

Tooltip

Medicine and Dentistry 3

38%

Social Sciences 3

38%

Biochemistry, Genetics and Molecular Bi... 2

25%

Article Metrics

Tooltip
Mentions
Blog Mentions: 1
News Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free
0